EC5026
Chronic Pain / Neuropathic Pain (Spinal Cord Injury)
Phase 1Active
Key Facts
Indication
Chronic Pain / Neuropathic Pain (Spinal Cord Injury)
Phase
Phase 1
Status
Active
Company
About EicOsis
EicOsis, founded in 2015 and based in Davis, California, is pioneering a new class of oral analgesics and anti-inflammatories by inhibiting the soluble Epoxide Hydrolase (sEH) enzyme. This mechanism increases endogenous fatty acid mediators to treat pain without the addictive potential of opioids. The company's lead program, EC5026, is in Phase 1 clinical development, with a specific trial for neuropathic pain from spinal cord injury funded by the Department of Defense. EicOsis represents a promising private venture targeting the massive unmet need in chronic pain treatment.
View full company profile